Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S509000, C514S419000, C548S507000, C548S537000
Reexamination Certificate
active
10849561
ABSTRACT:
Statin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases, in particular coronary syndromes, neurodegenerative disorders as well as for reducing cholesterol levels.
REFERENCES:
patent: 6476235 (2002-11-01), Butler et al.
patent: 97/16405 (1997-05-01), None
patent: WO 97/16405 (1997-05-01), None
patent: 98/21193 (1998-05-01), None
patent: WO 00/61537 (2000-10-01), None
patent: WO 00/61541 (2000-10-01), None
patent: WO 01/12584 (2001-02-01), None
patent: WO 03/007846 (2003-01-01), None
Carini, et al., “In Vitro Metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies,” J. Phar. Biomed. Anal. 29 (2002) 1061-71.
Chiroli, et al. “Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitorderivatives of asprin,” European J. Med. Chem. 38 (2003) 441-446. (available online Mar. 26, 2003).
Baraldi, et al. “Synthesis of Nitro Esters of PRedisolone, New Compounds Combining Pharmacological Properties of Both Glucocorticoids and Niitric Oxide,” J. Med. Chem. 2004, vol. 47, 711-719.
Burgaud, et al., Nitric Oxide-Releasing Drugs A Novel Class of Efective and Safe Therapeutic Agents, Ann. N.Y. Acad. Sci. 962: 360-371 (2002).
Hobbs, et al. “Achievement of English National Service Framework Lipid-lowering Goals: Pooled Data from Recent Comparative Treatment Trials of Statins at Starting Doses” J. Clin. Pract., vol. 59, 10 (2005), 1171-1177.
Omori, et al. “Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects,” British J. Clin. Pharmacol., vol. 54, 395, 399 (2002).
Shishehbor, et al., “Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways” Circulation. 2003; 108: 426-431.
Laufs, et al. “Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice Editorial Comment” Stroke, 2000: 32: 2442-2449.
Semeraro et al., “Direct Induction of Tissue Factor Synthesis by Endotoxin In Human Macrophages From Diverse Anatomical Sites,”Immunology50 529-535, 1983.
Vezza et al., “Prostaglandin E2Potentiates Platelet Aggregation by Priming Protein Kinase C,”Blood82 2704-2713, 1993.
Rossiello et al., “Fibrin Down-regulates LPS- and PMA-induced Tissue Factor Expression by Blood Momonuclear Cells,”Thromb Haemost84 453-459, 2000.
Momi et al., “Prevention of Pulmonary Thromboembolism by NCX 4016, a Nitric Oxide-Releasing Asprin,”European Journal of Pharmacology397 177-185, 2000.
Emanueli et al., “Local Delivery of Human Tissue Kallikrein Gene Accelerates Spontaneous Angiogenesis in Mouse Model of Hindlimb Ischemia,”Circulation2/9 125-132, 2001.
Wanstall et al., “Vascular Smooth Muscle Relaxation Mediated by Nitric Oxide Donors: A Comparison with Acetylcholine, Nitric Oxide and Nitroxyl Ion,”British Journal of Pharmacology134 463-472, 2001.
Bonetti et al., “Statin Effects Beyond Lipid Lowering—Are They Clinically Relevant?,”European Heart Journal24 225-248, 2003.
Ongini et al., Nitric Oxide (NO)-Releasing Statin Derivatives, A Class of Drugs Showing Enhanced Antoproliferative And Antiinflammatory Properties,PNAS101 8497-8502, 2004.
Bonazzi et al., “New Nitric Oxide (NO)-releasing Statin Derivatives With Enhanced Anti-Inflammatory Properties,”AHA Scientific Sessions9-12, 2003.
Dever et al., “Effects of No-Pravastatin on Leukocyte Adhesion and Reactive Oxygen Species Generation in Control and Apoe Knockout Mice,”AHA Scientific Sessions9-12, 2003.
Rossiello et al., “Nitropravastatin (NCX6550) Exerts an Antiplatelet/ Antithrombotic Activity and Inhabits Tissue Factor Expression,”AHA Scientific Sessions9-12, 2003.
Emanueli et al., “The Nitric Oxide (NO)-Releasing Pravastatin Derivative, NCX 6550, Potentiates Reparative Angiogenesis In A Mouse Model Of Peripheral Ischemia,”BPS, 2003.
Guzzetta et al., “Nitric Oxide (NO)-Releasing Statins: A New Class of Drugs Combining NO and Statin Properties,”BPS, 2003.
Momi et al., “Antiplatelet and Antithrombotic Activity of NCX 6550, A Nitrick Oxide (NO)-Releasing Derivative of Pravastatin,”BPS, 2003.
Guzzetta et al., “Novel Nitric Oxide (NO)-releasing Derivatives of Statins Modulate Cellular NO Homeostasis Acting on eNOS and iNOS Expressions,”9thInternational Conference on Alzheimer's Disease and Related Disorders, 2004.
Benedini Francesca
Del Soldato Piero
Ongini Ennio
Arent & Fox PLLC
Grazier Nyeemah
McKane Joseph K.
Nicox S.A.
LandOfFree
Statin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Statin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Statin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3792584